TP53 and cancer: The role of somatic mutations in p53, PTEN, and other classical tumor suppressor genes in TGCT remains contradictory, however TGCT response to cisplatin-based chemotherapy indicates cancer cell sensitivity to p53 activation (Gutekunst et al., 2011).